Investigational drug · Phase 3
CM336
Also called: group, QiShen YiQi Dripping Pills 3 bags
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma (MM), Primary Light-Chain Amyloidosis, Primary Immune Thrombocytopenia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
5 still active
All registered trials
20
Any phase or sponsor naming "CM336"
First trial start
2021
Jul 13, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CM336", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Multiple Myeloma (MM)
- Primary Light-Chain Amyloidosis
- Primary Immune Thrombocytopenia
- Autoimmune Cytopenia
- Immune Thrombocytopenia (ITP)
- Autoimmune Hemolytic Anemia
- Evans Syndrome
- Diabetic Kidney Disease
- Chronic Heart Failure With Reduced Ejection Fraction
Approved drugs for the same conditions: Heart failure · Multiple myeloma · Anemia · Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "CM336" as an intervention, largest first.
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT07910903 · 320 participants (planned) · Start Dec 2026 · Primary completion May 2030
Drug: CM336; CM313 and 3 more · For: Multiple Myeloma (MM)
Sites: Tianjin, China
- Study of CM336 in Relapsed or Refractory Multiple Myeloma PatientsPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT07181239 · 280 participants (planned) · Start Sep 2025 · Primary completion Sep 2027
Drug: CM336 Injection; Standard Of Care( SOC) · For: Multiple Myeloma (MM)
Sites: Tianjin, China
Keymed Biosciences Co.LtdIndustry
NCT07175493 · 158 participants (planned) · Start Nov 18, 2025 · Primary completion Nov 18, 2027
Drug: CM336 Injection · For: Autoimmune Cytopenia; Immune Thrombocytopenia (ITP); Autoimmune Hemolytic Anemia and 1 more
Sites: Zhengzhou, China; Changzhi, China; Tianjin, China
Keymed Biosciences Co.LtdIndustry
NCT07039578 · 90 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 30, 2026
Drug: CM336 Injection(Low dose group); CM336 Injection(High dose group) · For: Primary Light-Chain Amyloidosis
Sites: Beijing, China; Tianjin, China
Shandong First Medical UniversityAcademic, hospital or other
NCT06900010 · 70 participants (planned) · Start Apr 22, 2025 · Primary completion Jan 1, 2027
Drug: CM336 Injection · For: Autoimmune Bullous Disease
Sites: Jinan, China
- Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationNot yet recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07687004 · 50 participants (planned) · Start Aug 1, 2026 · Primary completion Aug 1, 2027
Drug: Sonrotoclax; CM336 (BCMA/CD3 bispecific antibody) · For: Multiple Myeloma (MM)
Sites: Tianjin, China
Keymed Biosciences Co.LtdIndustry
NCT05299424 · 48 participants (planned) · Start Aug 9, 2022 · Primary completion Dec 2026
Drug: CM336_group 1; CM336_group 2a and 13 more · For: Multiple Myeloma
Sites: Beijing, China
- CM336-SOC for Dynamically High-Risk Multiple Myeloma StudyNot yet recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07648459 · 46 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 9, 2027
Drug: anti-BCMA/CD3 bispecific antibody · For: Multiple Myeloma
- CM336 for Active Sjogren's Syndrome StudyNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT07642843 · 30 participants (planned) · Start Jun 2026 · Primary completion Apr 2028
Drug: CM336 · For: Primary Sjögren's Syndrome (pSS)
Sites: Beijing, China
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07585760 · 26 participants (planned) · Start Sep 10, 2026 · Primary completion May 1, 2028
Drug: CM336 Plus Isatuximab · For: Multiple Myeloma (MM); Multiple Myeloma Light Chain Induced Renal Insufficiency
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- Association Between the Expiration of Supplemental Nutrition Assistance Program Emergency Allotments and Child Maltreatment.
Zhang L, Wang Y, Ma R, et al. · Am J Prev Med 2028
- Trait-like proteomic signatures of stress resilience: correlates of freeze-like response resistance.
Kučera J, Makarová M, Vít M, et al. · Stress 2027
- Salivary oxytocin and testosterone in empathic stress responding: a pilot study.
Heilmann K, Walter M, Engert V · Stress 2027
- Microstate-specific functional connectivity in alcohol use disorder using resting-state EEG.
Park H, Yoo SY, Lee H, et al. · Dialogues Clin Neurosci 2027
- Pressure-guided pneumatic radial compression and radial artery occlusion after transradial coronary procedures: a retrospective historical cohort study.
Hu Y, Lv C, Zhou T, et al. · Scand Cardiovasc J 2027
- Effects of xylooligosaccharide supplementation on methane emissions, rumen microbiome, and serum metabolome in lactating Jersey cows.
Zhou X, Zhao Z, Zhao L, et al. · Anim Biotechnol 2027
Also in development for Multiple Myeloma (MM)
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- IDP-121Phase 22 trials
IDP Discovery Pharma S.L. · Small Cell Lung Cancer ( SCLC ), Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- BT02Phase 21 trial
Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.